1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer

Share this content:
Study findings suggest that 1 year of trastuzumab after primary therapy improves long-term disease-free survival.
Study findings suggest that 1 year of trastuzumab after primary therapy improves long-term disease-free survival.

Adjuvant trastuzumab for 1 year after chemotherapy significantly improved long-term disease-free survival compared with observation in women with HER2-positive early breast cancer, a study published in The Lancet has shown.1

Previous research has demonstrated that trastuzumab significantly improves overall survival and disease-free survival in patients with HER2-positive early breast cancer; however, additional follow-up data are needed to determine the long-term impact of trastuzumab treatment on clinical outcomes.

The international, open-label, phase 3 HERA trial (ClinicalTrials.gov Identifier: NCT00045032) enrolled 5099 women with HER2-positive early breast cancer and randomly assigned them 1:1:1 to receive trastuzumab for 1 year, trastuzumab for 2 years, or observation after completion of primary therapy with surgery, chemotherapy, and/or radiation therapy.

After a median follow-up of 11 years, results showed that adjuvant treatment with trastuzumab for 1 year significantly reduced the risk of recurrence by 24% (hazard ratio [HR], 0.76; 95% CI, 0.68-0.86) and death by 26% (HR, 0.74; 95% CI, 0.64-0.86) compared with observation.

There was no significant difference in disease-free survival between patients treated with 2 years of trastuzumab and those treated for 1 year (HR, 1.02; 95% CI, 0.89-1.17).

Investigators estimated that 69% of patients treated with trastuzumab for 1 year, 69% of those treated for 2 years, and 63% of those who received observation were disease-free at 10 years. More than half (52%) of patients initially assigned to observation crossed over to receive trastuzumab.

Fewer than 5% of patients in the 1-year trastuzumab group experienced cardiac toxicity compared with approximately 7% of patients in the 2-year trastuzumab group and approximately 1% of those in the observation arm.

The findings suggest that 1 year of trastuzumab after primary therapy improves long-term disease-free survival and overall survival, with no additional benefit from 2 years of trastuzumab, in this population.

Reference

1. Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017 Feb 16. doi: 10.1016/S0140-6736(16)32616-2 [Epub ahead of print]

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs